Understanding the Modulatory Effects of Cannabidiol on Alzheimer's Disease

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by amyloid beta (Aβ) and tau pathology, with current treatments offering limited efficacy.
• Existing therapies for AD provide symptomatic relief but do not halt disease progression.
• Cannabidiol (CBD), a non-psychoactive phytocannabinoid, exhibits neuroprotective properties via multiple receptor pathways.

Purpose of the Study:

• To review recent studies on the therapeutic effects of Cannabidiol (CBD) in Alzheimer's disease (AD).
• To explore the potential of CBD in mitigating AD pathology, including cognitive deficits, neuroinflammation, and protein aggregation.
• To identify challenges and future directions for translating CBD's preclinical benefits into clinical applications for AD.

Main Methods:

• Review of preclinical studies investigating CBD's effects in Alzheimer's disease models.
• Analysis of research focusing on CBD's impact on amyloid beta (Aβ) accumulation and tau hyperphosphorylation.
• Examination of studies exploring CBD's interaction with cannabinoid and non-cannabinoid receptors, such as peroxisome proliferator-activated receptor gamma.

Main Results:

• CBD has demonstrated efficacy in reversing cognitive deficits in AD mouse models.
• CBD treatment reduced neuroinflammatory and oxidative stress responses associated with Aβ.
• CBD administration led to decreased Aβ deposition and tau hyperphosphorylation, suggesting a potential to slow AD progression.

Conclusions:

• Cannabidiol (CBD) exhibits significant potential as a therapeutic agent for Alzheimer's disease (AD) by addressing core pathological hallmarks.
• CBD's ability to reverse cognitive deficits and reduce Aβ and tau pathology warrants further investigation.
• Understanding the precise mechanisms of CBD, particularly its interaction with receptors like PPARγ, is crucial for clinical translation.